TIDMPRTC
PureTech Health PLC
26 May 2022
26 May 2022
PureTech Health plc
PureTech Founded Entity Akili Integrates First-of-its-Kind
Prescription Video Game Treatment with the Virtual World Through
Partnership with Roblox
The Roblox vision for bringing people together through shared
experiences, plus the Akili commitment to a new era of cognitive
medicine, make the companies ideal partners to deliver a reimagined
patient experience
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company noted that its
Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading
digital medicine company pioneering the development of cognitive
treatments through game-changing technologies, and Roblox (NYSE:
RBLX), a global platform bringing millions of people together
through shared experiences, today announced a collaboration that
connects patients' medical treatments to their favorite virtual
worlds.
Through this partnership, Akili and Roblox are introducing new
ways for medicine to fit into patients' lives. Initially, the
companies will establish an exclusive Roblox rewards exchange tied
to Akili's EndeavorRx(R), the first and only prescription video
game treatment for children with ADHD, cleared by the U.S. Food and
Drug Administration (see full indication below). The companies are
exploring additional novel approaches and opportunities to engage
Akili patients through Roblox integrations.
The full text of the announcement from Akili is as follows:
Akili Integrates First-of-its-Kind Prescription Video Game
Treatment with the Virtual World Through Partnership with
Roblox
The Roblox vision for bringing people together through shared
experiences, plus the Akili commitment to a new era of cognitive
medicine, make the companies ideal partners to deliver a reimagined
patient experience
BOSTON, Mass. and SANTA MONICA, Calif. - May 26, 2022 - Akili
Interactive ("Akili"), a leading digital medicine company
pioneering the development of cognitive treatments through
game-changing technologies, and Roblox (NYSE: RBLX), a global
platform bringing millions of people together through shared
experiences, today announced a collaboration that connects
patients' medical treatments to their favorite virtual worlds.
"Roblox brings together tens of millions of people every day to
connect, create, and express themselves, and we're proud to be
working with Akili to leverage that passion and enjoyment in
connection with their first-in-class digital treatment," said Craig
Donato, Chief Business Officer of Roblox. "Akili has captured our
imagination with its prescription treatment for children with ADHD
delivered through an action video game experience and shares our
vision and enthusiasm for what's possible through interactive,
digital experiences. We're proud to help them as they lead the
effort to realize new potential in the field of medicine."
Through this partnership, Akili and Roblox are introducing new
ways for medicine to fit into patients' lives. Initially, the
companies will establish an exclusive Roblox rewards exchange tied
to Akili's EndeavorRx(R) treatment (see full indication below). The
companies are exploring additional novel approaches and
opportunities to engage Akili patients through Roblox
integrations.
"We are committed to improving the world's cognitive health
through treatments that engage and wow patients," said Eddie
Martucci, CEO and Co-Founder of Akili Interactive. "Our FDA-cleared
video game treatment demonstrates that medicine can be enjoyable,
and that is only the beginning. Akili's long-term vision aims to
integrate digital medicine into patients' daily lives in ways never
before seen or experienced. Roblox has changed how millions learn,
work, connect and play, and we are excited to work together to
further push the boundaries of our industries and continue to
redefine the experience of medicine."
Akili and Roblox are natural partners. Akili has challenged
traditional perceptions of medicine and created EndeavorRx(R) , the
first and only prescription video game treatment for children with
ADHD, cleared by the U.S. Food and Drug Administration (FDA). With
more than 55 million people worldwide coming together on Roblox
every day, Roblox is powering a platform for immersive, 3D shared
experiences. Together, they have the ability to reimagine the
patient experience.
EndeavorRx(R) Indication and Overview
EndeavorRx(R) is indicated to improve attention function as
measured by computer-based testing in children ages 8 to 12 years
old with primarily inattentive or combined-type ADHD, who have a
demonstrated attention issue. Patients who engage with
EndeavorRx(R) demonstrate improvements in a digitally assessed
measure Test of Variables of Attention (TOVA(R) ) of sustained and
selective attention and may not display benefits in typical
behavioral symptoms, such as hyperactivity. EndeavorRx(R) should be
considered for use as part of a therapeutic program that may
include clinician-directed therapy, medication, and/or educational
programs, which further address symptoms of the disorder.
EndeavorRx(R) is available by prescription only. It is not intended
to be used as a stand-alone therapeutic and is not a substitution
for a child's medication. EndeavorRx(R) associated adverse events
in clinical trials included frustration (6.1%), headache (1.3%),
dizziness (0.6%), emotional reaction (0.4%), nausea (0.4%), and
aggression (0.2%). No serious adverse events were associated with
its use. EndeavorRx(R) is recommended to be used for approximately
25 minutes a day, 5 days a week, over initially at least 4
consecutive weeks, or as recommended by your child's health care
provider. To learn more about EndeavorRx(R) , please visit
EndeavorRx.com.
About Roblox
Roblox is reimagining the way people come together to connect,
create and express themselves through immersive, interactive shared
experiences. Every day, millions of people around the world play,
learn, communicate, and expand their friendships as they explore
millions of user-generated digital experiences, all built by
creators on the platform. Our mission is to connect billions of
users with civility and optimism and support a safe and diverse
community - one that inspires and fosters creativity and positive
relationships among people around the world. For more information,
please visit corp.roblox.com.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Our approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine - medicine that is validated through
clinical trials like a drug or medical device but experienced like
entertainment. Akili's platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili's belief that
effective medicine can also be fun and engaging, Akili's products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com.
Forward-Looking Statements
This communication may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
"believe," "project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would, " "will be," "will continue," "will likely result,"
and similar expressions and include statements regarding Akili's
expectations for EndeavorRx(R) and digital medicine, its
partnership with Roblox and the benefits expected therefrom.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Akili to successfully commercialize EndeavorRx(R) and continue to
advance its clinical development pipeline, (ii) the ability of
Akili to maintain relationships with customers and suppliers and
retain its management and key employees, (iii) the evolution of the
markets in which Akili competes, (iv) the ability of Akili to
defend its intellectual property and satisfy regulatory
requirements, (v) the impact of the COVID-19 pandemic on Akili's
business, (vi) Akili's expectations regarding its market
opportunities and (vii) the risk of downturns and a changing
regulatory landscape in the highly competitive industry in which
Akili operates. The foregoing list of factors is not exhaustive.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Akili assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Akili does
not give any assurance that it will achieve its expectations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 25 therapeutics and therapeutic
candidates, including two that have received both U.S. FDA
clearance and European marketing authorization, as of the date of
PureTech's most recently filed Half Year Report and corresponding
Form 6-K. All of the underlying programs and platforms that
resulted in this pipeline of therapeutic candidates were initially
identified or discovered and then advanced by the PureTech team
through key validation points based on the Company's unique
insights into the biology of the brain, immune and gut, or BIG,
systems and the interface between those systems, referred to as the
BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those statements that relate to Akili's
expectations for EndeavorRx(R) and digital medicine, its
partnership with Roblox and the benefits expected therefrom, the
competitive environment in which Akili operates, and Akili and
PureTech's future prospects, development plans, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks, uncertainties and other
important factors that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other
important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2021
filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we
disclaim any obligation to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZGZKNKVGZZM
(END) Dow Jones Newswires
May 26, 2022 07:05 ET (11:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024